This research addresses the effect of COVID-19 on the tourism industry in general and on Malaysia in particular. This research explores the impact that the COVID-19 crisis has had on the tourism and tourism industry and hospitality services trends. To achieve the purpose of this research, first, the article explores the impact of the COVID-19 crisis on the impacts of the tourism industry, behaviours, and experiences for societal inclusion, together with international tourism disruption caused by Covid-19. The article discusses the significant impacts and experiences of COVID-19 on selected tourism supply chain members in Malaysia. Then, this paper provides a quick assessment of the reported procedures of the three major tourism stakeholders in Malaysian tourism (i.e., tourism demand, supply, government, and policymakers). This article finally draws on observation and reflections about the evolution of social inclusion through new forms of creative and niche tourism, accelerated by the COVID-19 crisis. For better or worse, an overview of the COVID-19 tourism impacts and implications thus suggests mitigation strategies for tourism research. Despite the industry's resilience in response to previous crises, the sheer depth and breadth of COVID-19-related impacts on tourism and the economy means a quick recovery is unlikely.

No abstract

No abstract

No abstract

Schizophrenia is a chronic psychiatric disorder and pharmacotherapy plays a major role in its management. The 1950s and early 1960s saw milestones in the introduction of psychotropic drugs in clinical practice. A review of drug prescriptions in different settings provides an insight into the pattern of drug use, identifies drug-related problems and may be used to compare recommended guidelines with actual practice. This effort led to the evaluation of the drug prescribing pattern of antipsychotics in patients attending the psychiatric clinic at a government hospital. The data from 371 antipsychotic medication prescriptions that included 200 prescriptions for schizophrenia were collected during one month (1rst-31rst August 2008) at the outpatient pharmacy department. The mean age of patients was 35.0 years (SD = 1.131), with a male to female ratio of 2:1. The most widely used oral antipsychotic was haloperidol (16.3%) while the most common depot preparation prescribed was zuclopenthixol decanoate (8.8%). The daily dose of the average antipsychotic prescribed in this clinic was 342.06 mg equivalent of chlorpromazine. There was no relation between the doses received and ethnicity of the patient (Malay, Chinese or Indian). However, there was a significant relationship between the prescribed dose and patient age (P < 0.042). Nearly 32% of the schizophrenia patients were prescribed with atypical antipsychotics such as olanzapine (10.8%), risperidone (10.0%), quetiapine (7.6%) and clozapine (3.2%). Monotherapy was given to 73.0% of the schizophrenia patients. The majority of patients also received antidepressants. To conclude, this study gave evidence that physicians had a strong preference for monotherapy with conventional antipsychotic drugs while the use of atypical drugs was less prevalent.